GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that reduces
inflammation in cells.
This study will evaluate three capsule and two tablet formulations to select the optimal
formulation for further development. Safety will be assessed through clinical laboratory
testing, 12-lead electrocardiogram (ECG), vital signs and Adverse Event/ Serious Adverse
Event (AE/ SAE) recording.